<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01891461</url>
  </required_header>
  <id_info>
    <org_study_id>BS12-000835</org_study_id>
    <nct_id>NCT01891461</nct_id>
  </id_info>
  <brief_title>Study to Compare the Addition of Floseal to Our Standard of Care to Control Post Operative Bleeding in TKR</brief_title>
  <official_title>A Prospective, Randomized Study to Compare the Addition of Granules of Gelatine + Thrombin to Our Standard of Care (SOC) to Control Post Operative Bleeding in Total Knee Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital du Sacre-Coeur de Montreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hopital du Sacre-Coeur de Montreal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare Floseal to our standard of care (SOC) to decrease
      intraoperative and immediate post-operative bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized single-blind clinical trial will be conducted at the Hôpital du
      Sacré-Coeur de Montréal and Hôpital Jean-Talon. All patients admitted for total knee
      arthroplasty (TKA) between January 2012 and September 2013 Outcome variable: Patient
      receiving Floseal or SOC

      Variables under study:

      Primary end point:

      Need of transfusion post-op (yes/no, how many)

      Patient will be transfused if :

      Hg &lt; 80 g/L plus if patient is symptomatic: orthostatic hypotension, tachycardia (pulse&gt;
      100/min, hypotension (&lt; 90/60), hx : CVA, CAD)

      Secondary end point:

        1. Efficacy (during hospital stay)

             -  Pre-op and post-op Hg (&gt; 100; 80-100; &lt;80)

             -  Hemovac blood drainage (ml)

             -  Per operative bleeding (ml)

        2. Safety (Follow up: 6wks, 6 ms, 12 ms, 24 ms)

             -  Post-op complications: infection, pain, oedema, allergic reaction.

             -  Functional outcomes: Knee Society Score (KSS), Western Ontario and McMaster
                Universities questionnaire (WOMAC), International knee documentation committee form
                (IKDC)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need of transfusion post-op (yes/no, how many)</measure>
    <time_frame>post op day 1 to 7</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Intraoperative Bleeding</condition>
  <condition>Post-operative Bleeding</condition>
  <arm_group>
    <arm_group_label>Floseal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Floseal will be administered during the procedure and prior to release of the tourniquet (if used PRN during the cementing procedure (±10 minutes)) and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissue by the use of a delivery syringe. Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
Preparation of Floseal requires mixing 5,000 US units of package thrombin (bovine-derived) made up to 5 milliliters of saline solution, to the Gelatin Matrix solution. In this study, 2-4 vials (15-20 mls total) will be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>For patients randomized to the control arm, the surgery will proceed in an otherwise identical fashion (with release of the tourniquet if used PRN during cementing procedure (±10 minutes)) and hemostasis followed by drain insertion and wound closure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Floseal</intervention_name>
    <description>Floseal (5 milliliters) will be applied to the exposed bone in the following order: around the margins of the tibia, the femur (anterior surface, intercondylar notch, exposed medial and lateral condyles) and around the un resurfaced portion of the patella. The other syringes (each of 5 milliliters) will then be applied to the supra-patellar synovium and into the medial and lateral gutters of the knee. No Floseal will be applied outside the knee joint capsule.</description>
    <arm_group_label>Floseal</arm_group_label>
    <other_name>Hemostatic Matrix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects above 18 years old admitted for a TKA between January 2012 and September
             2013at Hôpital du Sacré-Coeur de Montréal (HSCM) and Hôpital Jean-Talon (HJT),
             Montréal, Quebec, Canada.

               -  TKA done without the use of a tourniquet except while cementing only (±10
                  minutes)

               -  TKA done with Smith and Nephew &quot;Genesis II&quot; or Zimmer &quot;NexGen&quot; total knee
                  replacement implants

        Exclusion Criteria:

          -  • Prior osteotomy or knee surgery within last 6-8 wks

               -  Active, local infection or systemic infection

               -  Participation in any other pharmaceutical or clinical investigation

               -  Bleeding disorders (Hemophilia A, Hemophilia B, Von Willebrand disease, factor
                  VIII deficiency, Vitamin K deficiency, Thrombocytopenia (platelets &lt; 50 x 109 per
                  litre)

               -  Patients with known allergies to materials of bovine origin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio C Fernandes, MDMScMBAPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital du Sacre-Coeur de Montreal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital du sacre coeur de montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>June 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2013</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hopital du Sacre-Coeur de Montreal</investigator_affiliation>
    <investigator_full_name>Dr Julio Fernandes</investigator_full_name>
    <investigator_title>MD, MSc, MBA, PhD</investigator_title>
  </responsible_party>
  <keyword>total knee arthroplasty</keyword>
  <keyword>post-operative bleeding</keyword>
  <keyword>floseal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

